Chair (2025)
Hope Knuckles
Hope Knuckles has been working for more than 29 years at Abbott, in the Core Diagnostics Division, with over 19 years of management experience. She recently co-chaired the ASA Biopharm Regulatory-Industry Statistics Workshop in September 2022. She has provided statistical support for in-vitro assay development for hepatitis, retrovirus, and parasite blood screening assays and submissions to CBER. She has also managed submissions for in-vitro assays to CDRH in areas of Cardiac, Cancer, Thyroid/Metabolic, and Abused Drugs/Toxicology. Hope received her MS in Statistics from University of Louisiana at Lafayette, 1994, and her BS in Mathematics from Tennessee Technological University, 1992.
MDD Section Program Chair (2025)
Previous Roles: Section Representative (2020-2022), Program Chair Elect (2023)
Joanne Lin
Joanne is a trained biostatistician with exposure to both therapeutic and diagnostic areas and covers drugs and medical devices in various medical areas. In addition to her 2024 section program chair role, she also served as a section representative from 2020 to 2022
Council of Sections Representative (2023- 2025)
Xiaofeng Wang, PhD
Section Representative 2023 – 2025, Section of Medical Device and Diagnostics (MDD), American
Statistical Association

Treasurer (2022-2023; 2024)
Elysia Garcia

Communications Secretary (2024-2026)
Hari Sankaran

Correspondence Secretary (2024-2025)
Cristiana Mayer
Program Chair Elect (2024)
Ken (Guangxing) Wang, FDA
Student Paper Competition Chair (2025)
Adrijo Chakraborty

Adrijo Chakraborty is a statistician at the Center for Devices and Radiological Health, US Food and Drug Administration (FDA)
Past-Chair (2024)
Laura Yee

Laura Yee is a biostatistician at the National Cancer Institute (NCI) at the National Institutes of Health. Laura is currently Head of the Biostatistics and Data Management Section in the Center for Cancer Research at NCI. Prior to this role, at NCI’s Division of Cancer Treatment and Diagnosis, Laura worked primarily on precision medicine clinical trials to incorporate novel biomarkers into cancer therapy trials. Her background is in in vitro medical devices, having worked at FDA’s Center for Devices and Radiological Health. Laura has previously served as MDD Program Chair (2021), Correspondence Secretary (2017-2018), and as a reviewer for the Student Paper Committee (2017-2021).